SCHEMBL5336235

SCHEMBL5336235

CCc1nc(Cl)nc(Cl)c1F

nearest known ligand 0.32

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.32
ALDH1A1 P00352 1/20 0.30
ALOX15 P16050 1/20 0.30
TSHR P16473 1/20 0.30
GLA P06280 1/20 0.30
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12599748 0.80 LMNA (0.31) LMNA
SCHEMBL5343465 0.78 LMNA (0.30) LMNA
Ammonia Solution, Strong SCHEMBL27403923 0.78 LMNA (0.30) LMNA
SCHEMBL7997304 0.75 CYP1A2 (0.38)
SCHEMBL19462315 0.75 YTHDC1 (0.36) LMNA
SCHEMBL6992919 0.74 HTT (0.34) LMNAALDH1A1ALOX15TSHRGLA
SCHEMBL219104 0.74 ALDH1A1 (0.47) ALDH1A1ALOX15TSHR
SCHEMBL1553632 0.74
SCHEMBL3973149 0.74
SCHEMBL7993579 0.74 KDM4E (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115043780-B Synthesis method and application of 4-hydroxy-5-fluoro-6-ethylpyrimidine 上海飞琰化工科技有限公司 2024-01-16 CN disclosed
EP-3442947-B1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS EPIZYME INC (US) 2023-06-07 EP disclosed
EP-3442947-B1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS EPIZYME INC (US) 2023-06-07 EP disclosed
CN-115043780-A Synthesis method and application of 4-hydroxy-5-fluoro-6-ethylpyrimidine 上海飞琰化工科技有限公司 2022-09-13 CN disclosed
US-20210198277-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS Epizyme, Inc. 2021-07-01 US disclosed
US-20210198277-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS Epizyme, Inc. 2021-07-01 US disclosed
EP-3442947-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS Epizyme Inc (US) 2019-02-20 EP disclosed
US-20170355712-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS Epizyme, Inc. 2017-12-14 US disclosed
US-20170355712-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS Epizyme, Inc. 2017-12-14 US disclosed
US-20170355712-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS Epizyme, Inc. 2017-12-14 US disclosed
EP-0871625-B1 PREPARATION OF TRIAZOLES BY ORGANOMETALLIC ADDITION TO KETONES AND INTERMEDIATES THEREFOR PFIZER RES ANDDEVELOPMENT COMP (IE) 2003-12-17 EP disclosed
US-20030181720-A1 Preparation of triazoles by organometallic addition to ketones and intermediates therefor BUTTERS MICHAEL (GB) 2003-09-25 US disclosed
US-6586594-B1 Reacting 1-(2,4-difluorophenyl)-2-(1H-1,2,4-triazol-1-yl) ethanone and 6-(1-bromoethyl)-4-chloro-5-fluoropyrimidine in the presence of zinc, iodine, lewis acids, aprotic solvents and optionally lead to form sterospecific fungicides PFIZER, INC. 2003-07-01 US disclosed
EP-0871625-A1 PREPARATION OF TRIAZOLES BY ORGANOMETALLIC ADDITION TO KETONES AND INTERMEDIATES THEREFOR Pfizer Research and Development Company, N.V./S.A. (IE) 1998-10-21 EP disclosed
US-5773443-A Triazole antifungal agents PFIZER INC. (US) 1998-06-30 US disclosed
WO-1997006160-A1 PREPARATION OF TRIAZOLES BY ORGANOMETALLIC ADDITION TO KETONES AND INTERMEDIATES THEREFOR PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) 1997-02-20 WO disclosed
US-5567817-A Triazole antifungal agents PFIZER INC. (US) 1996-10-22 US disclosed
US-5278175-A Halopyridyl fungicides PFIZER INC. (US) 1994-01-11 US disclosed
EP-0440372-B1 TRIAZOLE ANTIFUNGAL AGENTS Pfizer Limited (GB) 1993-06-02 EP disclosed
EP-0440372-A1 Triazole antifungal agents Pfizer Limited (GB) 1991-08-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181720-A1 Preparation of triazoles by organometallic addition to ketones and intermediates therefor IKZF2, SLC39A11, IKZF3 LMNA 3334/4885ALDH1A1 180/4885ALOX15 75/4885
US-20170355712-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS SHMT1, BHMT, BHMT2 LMNA 3564/4885ALDH1A1 185/4885ALOX15 1053/4885
US-20210198277-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS SHMT1, BHMT, BHMT2 LMNA 3564/4885ALDH1A1 185/4885ALOX15 1053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.